Rehab Exoskeletons

An evidence-based analysis of ReWalk, Ekso, and Cyberdyne exoskeletons, evaluating shipping hardware status, clinical efficacy data, and availability within the Indian healthcare market.

An evidence-based assessment of commercial lower-limb exoskeletons, focusing on ReWalk, Ekso, and Cyberdyne HAL, with specific analysis on clinical efficacy and import viability for Indian healthcare providers.

An evidence-based assessment of active lower-limb exoskeletons from ReWalk, Ekso Bionics, and Cyberdyne HAL. This article evaluates shipping status, clinical efficacy data for spinal cord injury and stroke recovery, and the financial and regulatory realities of deploying these systems within Indian healthcare infrastructure.

An evidence-based review of shipping rehabilitation exoskeletons including ReWalk, Ekso Bionics, and Cyberdyne HAL. This analysis prioritizes regulatory clearance, clinical data, and actual deployment over concept demonstrations, with specific attention to availability and pricing within the Indian market.

An evidence-based analysis of shipping hardware from ReWalk, Ekso Bionics, and Cyberdyne HAL, focusing on clinical outcomes for spinal cord injury and stroke recovery, alongside availability and pricing data for the Indian healthcare sector.

An objective analysis of gait training exoskeletons, focusing on ReWalk, Ekso, and Cyberdyne HAL, with a grounded assessment of their clinical efficacy and commercial availability in India.

A grounded analysis of ReWalk, Ekso Bionics, and Cyberdyne HAL exoskeletons, prioritizing shipping hardware over concepts. This article evaluates clinical evidence, regulatory hurdles, and availability in the Indian market with landed cost estimates.

A grounded analysis of shipping lower-body exoskeletons from ReWalk, Ekso Bionics, and Cyberdyne HAL. This article evaluates clinical efficacy data, regulatory status, and the realistic cost of entry for Indian healthcare providers and patients.

An evidence-based assessment of the three dominant rehabilitation exoskeleton manufacturers—ReWalk Robotics, Ekso Bionics, and Cyberdyne—focusing on shipping hardware, clinical efficacy, and the current state of availability within the Indian healthcare landscape.

An analysis of shipping medical exoskeletons including ReWalk, Ekso Bionics, and Cyberdyne HAL. This report evaluates clinical evidence, regulatory status in India, and hardware availability without speculative hype.

An analysis of ReWalk, Ekso, and Cyberdyne HAL units focusing on deployed hardware, clinical outcomes, and India-specific availability and pricing.

A grounded review of lower-limb exoskeletons from ReWalk, Ekso, and Cyberdyne. Focus on shipping hardware, regulatory status, and Indian market entry barriers.

An evidence-based review of shipping rehabilitation exoskeletons including ReWalk, Ekso Bionics, and Cyberdyne HAL, evaluating clinical efficacy, hardware maturity, and India market entry barriers.

ReWalk, Ekso Bionics, and Cyberdyne HAL move beyond concept art. This review grades hardware availability, pilot deployments, and clinical evidence for medical-grade exoskeletons, with a specific focus on Indian market entry, CDSCO regulations, and landed cost estimates.

RobotWale covers CorTec Brain-Computer Interface Gets FDA Breakthrough Tag — what it means for the Indian robotics ecosystem, pricing, specs and deployment outlook.

A practical look at Rehab exoskeletons: what the clinical evidence shows as part of our Rehab Exoskeletons coverage in Healthcare & Assistive. What the machines actually do, how much they cost, and what Indian buyers and builders should know.

A practical look at ReWalk, Ekso and the exoskeleton ecosystem as part of our Rehab Exoskeletons coverage in Healthcare & Assistive. What the machines actually do, how much they cost, and what Indian buyers and builders should know.